Mary C. Long

544 total citations
19 papers, 438 citations indexed

About

Mary C. Long is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, Mary C. Long has authored 19 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Infectious Diseases, 8 papers in Epidemiology and 6 papers in Molecular Biology. Recurrent topics in Mary C. Long's work include Tuberculosis Research and Epidemiology (7 papers), HIV/AIDS drug development and treatment (7 papers) and Biochemical and Molecular Research (5 papers). Mary C. Long is often cited by papers focused on Tuberculosis Research and Epidemiology (7 papers), HIV/AIDS drug development and treatment (7 papers) and Biochemical and Molecular Research (5 papers). Mary C. Long collaborates with scholars based in United States. Mary C. Long's co-authors include William B. Parker, Edward P. Acosta, Ken B. Waites, Miles J. Novy, Lynn B. Duffy, Peta L. Grigsby, Vincent Escuyer, Terry K. Morgan, Drew W. Sadowsky and Jennifer R. King and has published in prestigious journals such as Journal of Bacteriology, The Journal of Infectious Diseases and American Journal of Obstetrics and Gynecology.

In The Last Decade

Mary C. Long

18 papers receiving 420 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary C. Long United States 14 204 195 165 62 61 19 438
Samuel Adeniyi‐Jones United States 11 158 0.8× 203 1.0× 148 0.9× 12 0.2× 51 0.8× 15 478
Annie Fang United States 13 117 0.6× 155 0.8× 59 0.4× 36 0.6× 40 0.7× 29 394
Izabelle Gadawski Canada 7 129 0.6× 99 0.5× 85 0.5× 26 0.4× 30 0.5× 9 333
Kazushige Nagai Japan 17 215 1.1× 212 1.1× 154 0.9× 73 1.2× 7 0.1× 30 853
Sarah Chauvin Canada 7 95 0.5× 34 0.2× 122 0.7× 19 0.3× 31 0.5× 8 404
Temi Lampejo United Kingdom 8 221 1.1× 125 0.6× 131 0.8× 33 0.5× 23 0.4× 24 495
Daniela E. Kirwan United Kingdom 12 198 1.0× 294 1.5× 81 0.5× 22 0.4× 16 0.3× 26 489
Demba Sarr United States 14 62 0.3× 34 0.2× 74 0.4× 43 0.7× 175 2.9× 30 457
Maha Al-Mozaini Saudi Arabia 12 73 0.4× 208 1.1× 84 0.5× 13 0.2× 23 0.4× 32 536
Emily Blodget United States 11 104 0.5× 116 0.6× 52 0.3× 9 0.1× 25 0.4× 23 304

Countries citing papers authored by Mary C. Long

Since Specialization
Citations

This map shows the geographic impact of Mary C. Long's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary C. Long with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary C. Long more than expected).

Fields of papers citing papers by Mary C. Long

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary C. Long. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary C. Long. The network helps show where Mary C. Long may publish in the future.

Co-authorship network of co-authors of Mary C. Long

This figure shows the co-authorship network connecting the top 25 collaborators of Mary C. Long. A scholar is included among the top collaborators of Mary C. Long based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary C. Long. Mary C. Long is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Robbins, Brian L., et al.. (2022). A Human Oral Fluid Assay for D‐ and L- Isomer Detection of Amphetamine and Methamphetamine Using Liquid‐Liquid Extraction. Journal of Analytical Methods in Chemistry. 2022(1). 4819599–4819599. 5 indexed citations
3.
Acosta, Edward P., Peta L. Grigsby, Kajal Larson, et al.. (2013). Transplacental Transfer of Azithromycin and Its Use for Eradicating Intra-amniotic Ureaplasma Infection in a Primate Model. The Journal of Infectious Diseases. 209(6). 898–904. 37 indexed citations
4.
Grigsby, Peta L., Miles J. Novy, Drew W. Sadowsky, et al.. (2012). Maternal azithromycin therapy for Ureaplasma intraamniotic infection delays preterm delivery and reduces fetal lung injury in a primate model. American Journal of Obstetrics and Gynecology. 207(6). 475.e1–475.e14. 88 indexed citations
5.
Ofotokun, Ighovwerha, Jeffrey L. Lennox, Molly E. Eaton, et al.. (2011). Immune Activation Mediated Change in Alpha-1-Acid Glycoprotein: Impact on Total and Free Lopinavir Plasma Exposure. The Journal of Clinical Pharmacology. 51(11). 1539–1548. 20 indexed citations
6.
Long, Mary C., Jennifer R. King, & Edward P. Acosta. (2009). Pharmacologic aspects of new antiretroviral drugs. Current HIV/AIDS Reports. 6(1). 43–50. 17 indexed citations
7.
Grigsby, Peta L., Mary C. Long, Miles J. Novy, et al.. (2009). 476: Transplacental pharmacokinetics (PK) and pharmacodynamics (PD) of azithromycin (AZI) treatment for intra-amniotic ureaplasma infection. American Journal of Obstetrics and Gynecology. 201(6). S179–S179. 1 indexed citations
8.
Long, Mary C., et al.. (2008). Structure–activity relationship for adenosine kinase from Mycobacterium tuberculosis. Biochemical Pharmacology. 75(8). 1588–1600. 22 indexed citations
9.
Long, Mary C., Jennifer R. King, & Edward P. Acosta. (2008). Pharmacologic aspects of new antiretroviral drugs. Current Infectious Disease Reports. 10(6). 522–9. 1 indexed citations
10.
Long, Mary C., et al.. (2008). A sensitive HPLC–MS–MS method for the determination of raltegravir in human plasma. Journal of Chromatography B. 867(2). 165–171. 27 indexed citations
11.
Long, Mary C., et al.. (2007). Development of a sensitive and specific liquid chromatography/mass spectrometry method for the determination of tenofovir in human plasma. Rapid Communications in Mass Spectrometry. 21(13). 2087–2094. 22 indexed citations
12.
Parker, William B. & Mary C. Long. (2007). Purine Metabolism in Mycobacterium tuberculosis as a Target for Drug Development. Current Pharmaceutical Design. 13(6). 599–608. 38 indexed citations
13.
Moore, Jeff D., Edward P. Acosta, Victoria A. Johnson, et al.. (2007). Intracellular Nucleoside Triphosphate Concentrations in HIV-Infected Patients on Dual Nucleoside Reverse Transcriptase Inhibitor Therapy. Antiviral Therapy. 12(6). 981–986. 22 indexed citations
14.
Long, Mary C. & William B. Parker. (2006). Structure–activity relationship for nucleoside analogs as inhibitors or substrates of adenosine kinase from Mycobacterium tuberculosis. Biochemical Pharmacology. 71(12). 1671–1682. 36 indexed citations
15.
Long, Mary C., et al.. (2006). Evaluation of 3-deaza-adenosine analogues as ligands for adenosine kinase and inhibitors of Mycobacterium tuberculosis growth. Journal of Antimicrobial Chemotherapy. 59(1). 118–121. 14 indexed citations
16.
Wang, Yimin, et al.. (2005). Overexpression, purification and crystallographic analysis of a unique adenosine kinase fromMycobacterium tuberculosis. Acta Crystallographica Section F Structural Biology and Crystallization Communications. 61(6). 553–557. 9 indexed citations
17.
Parker, William B., Esther W. Barrow, Paula W. Allan, et al.. (2004). Metabolism of 2-methyladenosine in Mycobacterium tuberculosis. Tuberculosis. 84(5). 327–336. 14 indexed citations
18.
Long, Mary C., Deborah J. Bidanset, Stephanie L. Williams, Nicole L. Kushner, & Earl R. Kern. (2003). Determination of antiviral efficacy against lymphotropic herpesviruses utilizing flow cytometry. Antiviral Research. 58(2). 149–157. 20 indexed citations
19.
Long, Mary C., Vincent Escuyer, & William B. Parker. (2003). Identification and Characterization of a Unique Adenosine Kinase from Mycobacterium tuberculosis. Journal of Bacteriology. 185(22). 6548–6555. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samuel Adeniyi‐Jones Breakdown of academic impact, for papers by Annie Fang Breakdown of academic impact, for papers by Izabelle Gadawski Breakdown of academic impact, for papers by Kazushige Nagai Breakdown of academic impact, for papers by Sarah Chauvin Breakdown of academic impact, for papers by Temi Lampejo Breakdown of academic impact, for papers by Daniela E. Kirwan Breakdown of academic impact, for papers by Demba Sarr Breakdown of academic impact, for papers by Maha Al-Mozaini Breakdown of academic impact, for papers by Emily Blodget
Rankless by CCL
2026